Checkpoint inhibition in meningiomas.
Immunotherapy
; 8(6): 721-31, 2016 06.
Article
en En
| MEDLINE
| ID: mdl-27197540
ABSTRACT
Meningiomas are increasingly appreciated to share similar features with other intra-axial central nervous system neoplasms as well as systemic cancers. Immune checkpoint inhibition has emerged as a promising therapy in a number of cancers, with durable responses of years in a subset of patients. Several lines of evidence support a role for immune-based therapeutic strategies in the management of meningiomas, especially high-grade subtypes. Meningiomas frequently originate juxtaposed to venous sinuses, where an anatomic conduit for lymphatic drainage resides. Multiple populations of immune cells have been observed in meningiomas. PD-1/PD-L1 mediated immunosuppression has been implicated in high-grade meningiomas, with association between PD-L1 expression with negative prognostic outcome. These data point to the promise of future combinatorial therapeutic strategies in meningioma.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Métodos Terapéuticos y Terapias MTCI:
Terapias_manuales
/
Drenaje_linftico
Asunto principal:
Neoplasias del Sistema Nervioso Central
/
Neoplasias Hematológicas
/
Inmunoterapia
/
Meningioma
/
Antineoplásicos
Idioma:
En
Revista:
Immunotherapy
Año:
2016
Tipo del documento:
Article
País de afiliación:
Estados Unidos